Response to replacing ranibizumab with bevacizumab on the pharmaceutical benefits scheme: Where does the current evidence leave us?

Clinical and Experimental Optometry

Volumn 95, Issue 5, 2012, Pages 541-543

  O'Shea, John G ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Anti VEGF treatments; Bevacizumab; Macular degeneration; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A;

COST BENEFIT ANALYSIS; DRUG ANTAGONISM; DRUG COST; HUMAN; NOTE; RETINA MACULA DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865558462     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2012.00736.x     Document Type: Note

References (24)

1. Aujla JS. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us? Clin Exp Optom 2012; 95: 538-540.
2. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 14: 510-512.
3. The CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
4. Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Ophthalmologia 2009; 223: 370-375.
5. Fong, DS Custis, P Howes, J, Jin-Wen Hsu, JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010; 117: 298-302.
6. Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR etal. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2009; 29: 1067-1073.
7. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S et al Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009; 148: 875-882.
8. Statement from the American Academy of Ophthalmology regarding the results of the Comparison of AMD Treatment Trials. 27 April 2011.
9. Martin DF, Maguire MG, Fine S. Bevacizumab: not as good with more adverse reactions? Response. Clin Experiment Ophthalmol 2011; 39: 718-720.
10. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-1739.
11. Ueta T, Yanagi Y, Tamaki T, Yamaguchi T. Cerebrovascular accidents with ranibizumab. Ophthalmology 2009; 116: 362.
12. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J etal. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010; 340: c2459.
13. Sheybani A, Kymes S, Schlief S, Apte R. Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Retina 2009; 29: 1404-1408.
14. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
15. Fung AE, P J Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349.
16. Al-Qureshi S, Shaikh S. Intravenous bevacizumab adult safety data: the evidence so far. Clin Experiment Ophthalmol 2012; 40: 3-5.
17. Beaumont P. Bevacizumab: not as good with more adverse reactions? Clin Experiment Ophthalmol 2011; 39: 588-590.
18. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-512.
19. O'Shea JG. Excessive cost of Lucentis. Aust J Pharm 2010; 91: 8.
20. Abeysiri P, Johnston NR, Molteno AC. Price of bevacizumab for intravitreal injection in New Zealand. Clin Experiment Ophthalmol 2010; 38: 84.
21. O'Shea JG. Implications of the NIH CATT Study for optometrists and for primary eye care. Australian Optometry September 2011. p 12.
22. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012; 13: 585-591.
23. Pharmaceutical Benefits Advisory Board. Public Summary Document, March 2007. Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/8273CE4F07D2021FCA2572F800047B3B/$File/Ranibizumab.pdf.
24. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244-1246.